HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART). (HYPART)
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART): A Non-inferiority, Open-label, Phase III Randomized Trial.
Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
A NA clinical study on Breast Cancer and Hypofractionation, this trial is actively recruiting participants. The trial is conducted by Post Graduate Institute of Medical Education and Research, Chandigarh and has accumulated 10 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Jul 2025 — Present [monthly]
Recruiting NA
-
Sep 2024 — Jul 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
-
Apr 2024 — May 2024 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Jan 2023 — Apr 2024 [monthly]
Recruiting NA
-
Sep 2021 — Jan 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Not Yet Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Post Graduate Institute of Medical Education and Research, Chandigarh
For direct contact, visit the study record on ClinicalTrials.gov .